ArticleVirology2011
Dominant role of HPV16 E7 in anal carcinogenesis.
Article in Virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Rational Design of Stapled Covalent Peptide Modifiers of Oncoprotein E6 from Human Papillomavirus.ACS chemical biology · 2025Article
- Highlights into historical and current immune interventions for cancer.International immunopharmacology · 2023Review
- Metastatic or Locally Recurrent Anal Squamous Cell Carcinoma (SCAC): Current Clinical Trial Landscape and Novel Approaches.Cancer management and research · 2022Review
- A Novel Model for Papillomavirus-Mediated Anal Disease and Cancer Using the Mouse Papillomavirus.mBio · 2021Article
- Viruses in Cancers of the Digestive System: Active Contributors or Idle Bystanders?International journal of molecular sciences · 2020Review
- Mus musculus Papillomavirus 1: a New Frontier in Animal Models of Papillomavirus Pathogenesis.Journal of virology · 2020Review
- Activating Mutations inClinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Basic Science, Epidemiology, and Screening for Anal Intraepithelial Neoplasia and Its Relationship to Anal Squamous Cell Cancer.Clinics in colon and rectal surgery · 2018Review
- The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis.Virology · 2017Article
- Recent advances in preclinical model systems for papillomaviruses.Virus research · 2017Review
- Characterization of topoisomerase II α and minichromosome maintenance protein 2 expression in anal carcinoma.Oncology letters · 2017Article
- HPV disease transmission protection and control.Microbial cell (Graz, Austria) · 2016Review
- Revealing potential molecular targets bridging colitis and colorectal cancer based on multidimensional integration strategy.Oncotarget · 2015Article
- Review
- Model systems to study the life cycle of human papillomaviruses and HPV-associated cancers.Virologica Sinica · 2015Review
- Anal cancer and intraepithelial neoplasia: epidemiology, screening and prevention of a sexually transmitted disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Review
- Noninvasive assessment of mitochondrial organization in three-dimensional tissues reveals changes associated with cancer development.International journal of cancer · 2015Article
- Optimal treatment strategies for anal cancer.Current treatment options in oncology · 2014Review
- The papillomavirus E7 proteins.Virology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Ninety percent of anal cancer is associated with human papilloma viruses (HPVs). Using our previously established HPV transgenic mouse model for anal cancer, we tested the role of the individual oncogenes E6 and E7. K14E6 and K14E7 transgenic mice were treated with dimethylbenz[a]anthracene (DMBA) to the anal canal and compared to matched nontransgenic and doubly transgenic K14E6/E7 mice. K14E7 and K14E6/E7 transgenic mice developed anal tumors (papillomas, atypias and carcinomas combined) at significantly higher rates (88% and 100%, respectively) than either K14E6 or NTG mice (18% and 19%, respectively). Likewise, K14E7 and K14E6/E7 transgenic mice developed frank cancer (carcinomas) at significantly higher rates (85% and 85%, respectively) than either K14E6 or NTG mice (18% and 10%, respectively). These findings indicate that E7 is the more potent oncogene in anal cancer caused by HPVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.